Arcturus Therapeutics Holdings Inc. (ARCT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US03969T1097
Arcturus Therapeutics Holdings Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 82.03 m USD |
| Operating income | -76.26 m USD |
| EBIT | -65.78 m USD |
| Net income | -65.78 m USD |
| Diluted EPS – continuing operations | -2.40 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
More stocks
- Fabryka Farb i Lakierów ŚNIEŻKA SA (SKA.WA)
- Hallacast Co.,Ltd (125490.KQ)
- Zhejiang Walrus New Material Co Ltd (003011.SZ)
- Samyang Holdings (000070.KS)
- Terra Innovatum Global N.V. (NKLR)
- UD Electronic (3689.TWO)
- Maritima De In (MARINSA.SN)
- Trivago NV (TRVG)
- Opus Genetics, Inc. (IRD)
- Kcc Glass Corp (344820.KS)
- Shiyan Taixiang Industry Co. Ltd. A (301192.SZ)
- Linedata Services S.A. (LIN.PA)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.